<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517192</url>
  </required_header>
  <id_info>
    <org_study_id>1182.71</org_study_id>
    <nct_id>NCT00517192</nct_id>
  </id_info>
  <brief_title>Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to &gt; 1 PI</brief_title>
  <official_title>A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of PrezistaÂ® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir
      (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600
      mg /100 mg twice daily) in combination with investigator selected optimised background
      regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI),
      Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI))
      treatment-experienced (a minimum of 3-months duration for each class) with resistance to more
      than one PI on the screening virtual phenotype resistance testing.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Virologic Failure Through 48 Weeks of Treatment, Using Viral Load (VL) &lt; 50 Copies/Millilitre (mL) as the Response Criterion.</measure>
    <time_frame>48 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion and the FDA Definition for Handling Drug Discontinuations ((NCF) Non-Completers=Failure).</measure>
    <time_frame>48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent-To-Treat Analysis of Virologic Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion Where Patients Are Followed Until Week 48 for VL Regardless of Whether or Not They Remain on Study Drug.</measure>
    <time_frame>48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Virologic Failure Through 48 Weeks of Treatment, Using VL &lt; 400 Copies/mL as the Response Criterion.</measure>
    <time_frame>48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Censored</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using NCF</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Intent-to-treat</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Censored</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using NCF</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Intent-to-treat</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Censored</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using NCF</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Intent-to-treat</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in CD4+ Cell Count Change From Baseline at up to Week 8</measure>
    <time_frame>up to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in CD4+ Cell Count Change From Baseline up to Week 24</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in CD4+ Cell Count Change From Baseline up to Week 48</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in Viral Load Change From Baseline up to Week 8</measure>
    <time_frame>up to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in Viral Load Change From Baseline up to Week 24</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average in Viral Load Change From Baseline up to Week 48</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count up to Week 48</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 Viral Load up to Week 48</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of New AIDS Progression Events or Death</measure>
    <time_frame>through 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent prior to trial participation.

          2. HIV-1 infected male or female &gt;18 years of age.

          3. Three-class (NRTI, NNRTI, and PI) treatment-experienced patients (a minimum of
             3-months duration for each class or documented class hypersensitivity/intolerance)
             with resistance (minimal or reduced response) to more than one PI on the screening
             virtual phenotype resistance testing. In the case of NNRTIs, NNRTI resistance in the
             absence of exposure is equivalent to being NNRTI treatment experienced.

          4. Patient's optimized background regimen must contain one of the following ARV options:

               -  A minimum of two genotypically active nucleoside/nucleotide reverse transcriptase
                  inhibitors (NRTIs) reported as &quot;maximal response&quot; or &quot;sensitive&quot; on the screening
                  virtual phenotype report.

               -  A minimum of one genotypically active NRTI reported as &quot;maximal response&quot; or
                  &quot;sensitive&quot; on the screening virtual phenotype report plus Enfuvirtide if not
                  used previously.

               -  A minimum of one genotypically active NRTI reported as &quot;maximal response&quot; or
                  &quot;sensitive&quot; on the screening virtual phenotype report plus an integrase inhibitor
                  if not used previously and if available through an expanded access program and
                  allowed by local regulatory authorities.

               -  A minimum of one genotypically active NRTI reported as &quot;maximal response&quot; or
                  &quot;sensitive&quot; on the screening virtual phenotype report plus the CCR5 chemokine
                  receptor antagonist Maraviroc if available through an expanded access program,
                  not used previously and allowed by local regulatory authorities.

               -  Zero or one genotypically active NRTI reported as &quot;maximal response&quot; or
                  &quot;sensitive&quot; on the screening virtual phenotype report plus two of the following
                  drugs, Enfuvirtide, an integrase inhibitor and Maraviroc if available, not used
                  previously and allowed by local regulatory authorities.

               -  Two genotypically partially active NRTIs (provided that they are not part of the
                  current failing regimen) reported as &quot;reduced response&quot; on the screening virtual
                  phenotype report plus one of the following drugs, Enfuvirtide, an integrase
                  inhibitor or Maraviroc if available, not used previously and allowed by local
                  regulatory authorities.

          5. Patient has been on their current (failing) PI-containing regimen for at least 8 weeks
             prior to randomization.

          6. Patient has on-going viral replication (defined as an HIV-1 viral load of â¥ 500
             copies/mL) and a successful virtual phenotype obtained at screening.

          7. Any baseline CD4 cell count will be allowed.

          8. Karnofsky performance score of â¥ 70.

          9. Acceptable screening laboratory values that indicate adequate baseline organ function.
             Laboratory values are considered acceptable if the following apply:

               -  ALT â¤2.5 x ULN and AST â¤2.5 x ULN (â¤DAIDS Grade 1, Appendix 10.1).

               -  Any DAIDS grade cholesterol, triglycerides, GGT, CPK or LDH is acceptable.

               -  All other laboratory test values must be â¤DAIDS Grade 2.

         10. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent
             opportunistic infections.

         11. Willingness to abstain from ingesting substances which may alter plasma study drug
             levels by interaction with the cytochrome P450 system during the study.

        Inclusion Criteria:

          1. Previous use of Tipranavir (TPV) or Darunavir (DRV).

          2. Full genotypic resistance (reported as minimal response) to Tipranavir (TPV) or
             Darunavir (DRV) on screening virtual phenotype:

          3. Female patient of child-bearing potential who:

             has a positive serum pregnancy test at screening, is breast feeding, is planning to
             become pregnant, is not willing to use double-barrier methods (simultaneous use of two
             different methods such as diaphragm with spermicidal substance and condom) of
             contraception or requires ethinyl estradiol administration. Barrier methods of
             contraception include diaphragm with spermicidal substance, condom for females,
             cervical caps and condoms.

          4. History of Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma
             (KS), and/or any malignancy.

          5. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment
             for at least 12 weeks at screening visit.

          6. Use of immunomodulatory drugs (such as interferon, cyclosporin, hydroxyurea and
             interleukin 2) within 30 days prior to randomization.

          7. Current use of systemic cytotoxic chemotherapy.

          8. All contraindications listed in the product monographs of Aptivus, Prezista and
             Norvir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1182.71.1109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nassau</city>
        <country>Bahamas</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tourcoing cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antella (fi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3916 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3919 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.1129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.3408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok Noi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.71.6603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phathumwan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bahamas</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <results_first_submitted>September 18, 2009</results_first_submitted>
  <results_first_submitted_qc>September 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2009</results_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
          <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
        <group group_id="P2">
          <title>Darunavir 600 mg/Ritonavir 100 mg</title>
          <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early termination of the trial</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
          <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
        <group group_id="B2">
          <title>Darunavir 600 mg/Ritonavir 100 mg</title>
          <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="6.1"/>
                    <measurement group_id="B2" value="43.1" spread="6.2"/>
                    <measurement group_id="B3" value="43.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Virologic Failure Through 48 Weeks of Treatment, Using Viral Load (VL) &lt; 50 Copies/Millilitre (mL) as the Response Criterion.</title>
        <time_frame>48 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virologic Failure Through 48 Weeks of Treatment, Using Viral Load (VL) &lt; 50 Copies/Millilitre (mL) as the Response Criterion.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion and the FDA Definition for Handling Drug Discontinuations ((NCF) Non-Completers=Failure).</title>
        <time_frame>48 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion and the FDA Definition for Handling Drug Discontinuations ((NCF) Non-Completers=Failure).</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent-To-Treat Analysis of Virologic Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion Where Patients Are Followed Until Week 48 for VL Regardless of Whether or Not They Remain on Study Drug.</title>
        <time_frame>48 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Intent-To-Treat Analysis of Virologic Response at Week 48, Using VL &lt; 50 Copies/mL as the Response Criterion Where Patients Are Followed Until Week 48 for VL Regardless of Whether or Not They Remain on Study Drug.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Virologic Failure Through 48 Weeks of Treatment, Using VL &lt; 400 Copies/mL as the Response Criterion.</title>
        <time_frame>48 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virologic Failure Through 48 Weeks of Treatment, Using VL &lt; 400 Copies/mL as the Response Criterion.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Censored</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Censored</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using NCF</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using NCF</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Intent-to-treat</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 50 Copies/mL Using Intent-to-treat</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Censored</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Censored</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using NCF</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using NCF</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Intent-to-treat</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using VL &lt; 400 Copies/mL Using Intent-to-treat</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Censored</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Censored</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using NCF</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using NCF</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Intent-to-treat</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Intent-to-treat</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in CD4+ Cell Count Change From Baseline at up to Week 8</title>
        <time_frame>up to week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in CD4+ Cell Count Change From Baseline at up to Week 8</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in CD4+ Cell Count Change From Baseline up to Week 24</title>
        <time_frame>up to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in CD4+ Cell Count Change From Baseline up to Week 24</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in CD4+ Cell Count Change From Baseline up to Week 48</title>
        <time_frame>up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in CD4+ Cell Count Change From Baseline up to Week 48</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in Viral Load Change From Baseline up to Week 8</title>
        <time_frame>up to week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in Viral Load Change From Baseline up to Week 8</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in Viral Load Change From Baseline up to Week 24</title>
        <time_frame>up to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in Viral Load Change From Baseline up to Week 24</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average in Viral Load Change From Baseline up to Week 48</title>
        <time_frame>up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average in Viral Load Change From Baseline up to Week 48</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count up to Week 48</title>
        <time_frame>up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count up to Week 48</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 Viral Load up to Week 48</title>
        <time_frame>up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 Viral Load up to Week 48</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of New AIDS Progression Events or Death</title>
        <time_frame>through 48 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
            <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 600 mg/Ritonavir 100 mg</title>
            <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of New AIDS Progression Events or Death</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signing of the informed consent onwards through the observational phase (50 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tipranavir 500 mg/Ritonavir 200 mg</title>
          <description>Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
        <group group_id="E2">
          <title>Darunavir 600 mg/Ritonavir 100 mg</title>
          <description>PrezistaÂ® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Iliac artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

